Cappella Medical Devices has received Indian regulatory approval for its Sideguard Coronary Stent system.
The Sideguard system includes the company’s proprietary stent design and balloon delivery system, which provides interventional cardiologist a solution to prvoide side branch preservation and ostial protection, thus enabling enhanced care for patients across a wide range of bifurcation lesions.
Cappella VP Commercial Operations David Blossom said now, clinicians in India will be able to utilize the company’s Sideguard system, a technology dedicated to bifurcation disease that scaffolds the ostium reducing plaque and carina shift while preserving the sidebranch.
The Cappella Sideguard system has received CE mark approval and is being distributed throughout Europe, South America, and Canada.